Annual Meeting 2014: A phase 1 trial of MK-3475 combined with Len and Lo-dose Dex in patients with RRMM

Annual Meeting 2014: A phase 1 trial of MK-3475 combined with Len and Lo-dose Dex in patients with RRMM

440 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) RRMM patients refractory to proteasome inhibitors and immunomodulatory drugs (IMiD) have a very poor outcome. PD-L1 expressed on most MM plasma cells is a potential mechanism of immune evasion. MK-3475 is a potent, highly selective, humanized IgG4/kappa isotype, anti-PD-1 monoclonal antibody designed to block PD-1 interaction with PD-L1 and PD-L2, enhancing lymphocytic activity, tumor regression and immune rejection. Visit our website at: http://www.myeloma.org
Up Next Autoplay
User Photo